Literature DB >> 12795242

Use of prior information to stabilize a population data analysis.

Per O Gisleskog1, Mats O Karlsson, Stuart L Beal.   

Abstract

When modeling new data with a complex population pharmacokinetic/pharmacodynamic model, there may not be sufficient information to obtain estimates of all parameters. In this case information from previous studies can also be used to help stabilize estimation. Using simulated data, we explored three different ways to do this. (i) Some parameter values were fixed to estimates obtained from earlier data. (ii) The earlier data were combined with the current data. (iii) The objective function based on the current data was augmented by a penalty function expressing summary information obtained from the earlier data. This last method is similar to the use of a Bayesian prior. It may be particularly useful when either the combined data set of method (ii) is very large and leads to large computation times or when the early data are not readily available. With this method, two different types of penalty functions were used. With our examples, the three methods all resulted in stabilized estimation. Methods (ii) and (iii) gave similar results for parameter and standard error estimation, especially with respect to fixed effects parameters. For hypothesis testing, results obtained with method (i) are very problematic. There are also problems with the results obtained with method (iii), but they are much less severe, and when the design for the earlier data is known, they can be corrected by using a computer-intensive simulation test procedure.

Mesh:

Year:  2002        PMID: 12795242     DOI: 10.1023/a:1022972420004

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.

Authors:  L E Simonsen; U Wählby; M Sandström; A Freijs; M O Karlsson
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Commentary on significance levels for covariate effects in NONMEM.

Authors:  Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

4.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

5.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

6.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

7.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

8.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

  8 in total
  56 in total

1.  Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Authors:  Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

3.  The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.

Authors:  Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
Journal:  AAPS J       Date:  2004-08-11       Impact factor: 4.009

4.  Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.

Authors:  Matthew M Hutmacher; Debu Mukherjee; Kenneth G Kowalski; David C Jordan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 5.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

6.  Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Authors:  Jakob Ribbing; Andrew C Hooker; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

7.  The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Authors:  Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-14       Impact factor: 2.745

Review 8.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

9.  Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

Authors:  Maria C Kjellsson; Per-Henrik Zingmark; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-23       Impact factor: 2.745

10.  Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

Authors:  Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María Del Mar Fernández de Gatta; Jesús María Hernández-Rivas; Alejandro Martín; María José García
Journal:  Br J Clin Pharmacol       Date:  2016-09-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.